title: [The role of Tim-3 mRNA in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
abstract: OBJECTIVE
  To investigate the role of Tim-3 gene expression in acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  
  
  METHODS
  Patients after allo-HSCT were retrospectively analyzed, this cohort of patients were divided into different groups according to disease states (grade 0-Ⅰ aGVHD group, grade Ⅱ-Ⅳ aGVHD group, improved aGVHD group) and time periods (+14-+30 d, +31-+60 d, +61-+100 d) to compare PBMC Tim-3 mRNA expression and plasma IFN-γ, IL-2 concentrations among them.
  
  
  RESULTS
  RT-PCR showed that in grade 0-Ⅰ aGVHD group, Tim-3 mRNA expression in patients +31-+60 d (7.24±2.79) was significantly higher than that in patients + 14-+ 30 d (4.60±1.66) and + 61-+ 100 d (3.86±1.36) (P<0.05). Tim-3 mRNA expressions of grade Ⅱ-Ⅳ aGVHD group in patients +14-+30 d, +31-+60 d, +61-+100 d were 9.54± 3.05, 10.14±3.28, 12.82±4.20, respectively, which in both +14-+30 d and +61-+100 d were significantly higher than that of grade 0-Ⅰ aGVHD and improved aGVHD groups (P<0.05). In patients +31-+60 d, Tim-3 expression of grade Ⅱ-Ⅳ aGVHD group was higher than improved aGVHD group (2.49±0.89), while no statistical difference when compared with grade 0-Ⅰ aGVHD group (7.24±2.79). In grade Ⅱ-Ⅳ aGVHD group, Tim-3 mRNA expression manifested no statistical difference among grades or organ involved (P>0.05). ELISA results showed that plasma IFN-γ and IL-2 concentrations were higher in grade Ⅱ-Ⅳ aGVHD group than of other groups, while no significant difference existed between grade 0-Ⅰ aGVHD and improved aGVHD groups (P<0.05).
  
  
  CONCLUSIONS
  Tim-3 played an important role in the process of aGVHD.
authors.affiliation: Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Jiangsu Clinical Medicine Center, Suzhou 215006, China.
authors.forename: X L
authors.initials: XL
authors.lastname: Li
authors.forename: Y
authors.initials: Y
authors.lastname: Yao
authors.forename: B Y
authors.initials: BY
authors.lastname: Yang
authors.forename: L J
authors.initials: LJ
authors.lastname: Xu
authors.forename: B
authors.initials: B
authors.lastname: Liu
authors.forename: M
authors.initials: M
authors.lastname: Che
authors.forename: Y B
authors.initials: YB
authors.lastname: Zhu
authors.forename: X J
authors.initials: XJ
authors.lastname: Wu
authors.affiliation: Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Jiangsu Clinical Medicine Center, Suzhou 215006, China.
authors.forename: D P
authors.initials: DP
authors.lastname: Wu
mesh_terms: D004797:Enzyme-Linked Immunosorbent Assay; D015870:Gene Expression; D006086:Graft vs Host Disease / Q000378:metabolism*; D018380:Hematopoietic Stem Cell Transplantation; D000072597:Hepatitis A Virus Cellular Receptor 2 / Q000378:metabolism*; D006801:Humans; D007371:Interferon-gamma / Q000097:blood; D007376:Interleukin-2 / Q000097:blood; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D012189:Retrospective Studies; D014184:Transplantation, Homologous
chemical_list: C448908:HAVCR2 protein, human; D000072597:Hepatitis A Virus Cellular Receptor 2; C573415:IFNG protein, human; C508594:IL2 protein, human; D007376:Interleukin-2; D012333:RNA, Messenger; D007371:Interferon-gamma